Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Rhea-AI Summary

Terns Pharmaceuticals (NASDAQ: TERN) said senior management will participate in multiple investor conferences in March 2026, including TD Cowen, Leerink, Barclays, and The Citizens Life Sciences conferences. Live fireside chat webcasts and replays will be available on the company's investor relations site for at least 30 days.

Key Figures

TD Cowen conference time: 3:50 p.m. ET Leerink conference time: 1:40 p.m. ET Citizens conference time: 9:00 a.m. ET +1 more

4 metrics

TD Cowen conference time 3:50 p.m. ET TD Cowen 46th Annual Health Care Conference, March 2, 2026

Leerink conference time 1:40 p.m. ET Leerink Global Healthcare Conference, March 9, 2026

Citizens conference time 9:00 a.m. ET Citizens Life Sciences Conference, March 11, 2026

Webcast archive period 30 days Duration webcasts remain archived on company website

Market Reality Check

Price: $41.45 Vol: Volume 1,265,142 is below...

low vol

$41.45 Last Close

Volume Volume 1,265,142 is below the 20-day average of 1,921,697, suggesting no unusual trading ahead of this conference update. low

Technical Trading above the 200-day MA, with price at $41.45 versus MA(200) at $16.76, indicating an established uptrend before this news.

Peers on Argus

Among close biotech peers, moves are mixed: gains in names like SEPN (+9.36%) an...

1 Up

Among close biotech peers, moves are mixed: gains in names like SEPN (+9.36%) and NRIX, but also a decline in BCAX (-1.52%). With only modest peer activity and no broad, same-direction move, today’s setup looks stock-specific rather than a sector-wide rotation.

Historical Context

5 past events · Latest: Feb 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 02	Inducement grants	Neutral	+6.4%	Equity options granted to new employees under inducement award plan.
Jan 07	Conference priorities	Positive	-5.6%	Outlined 2026 priorities and detailed TERN-701 clinical and cash runway plans.
Jan 02	Inducement grants	Neutral	-2.3%	Stock options granted to new employees under Nasdaq Listing Rule 5635(c)(4).
Dec 11	Offering closing	Neutral	+5.6%	Closed underwritten public offering including full exercise of underwriters’ option.
Dec 09	Offering pricing	Neutral	+5.8%	Priced upsized public offering of common stock at $40.00 per share.

Pattern Detected

Recent news has included equity offerings and inducement grants, with generally positive or moderate price responses, suggesting the stock has absorbed financing and compensation-related events without consistent downside pressure.

Recent Company History

Over the last few months, Terns has focused on financing, corporate actions, and program visibility. In December 2025, it priced and then closed a sizable public offering at $40.00 per share, with gross proceeds of $650 million and then $747.5 million, both followed by mid-single-digit percentage gains. Early 2026 brought multiple inducement and director option grants tied to Nasdaq rules and board compensation, with mixed but contained price reactions. A January J.P. Morgan presentation outlined detailed 2026 priorities and TERN‑701 milestones, showing an execution focus that contextualizes today’s investor-conference participation.

Market Pulse Summary

This announcement details Terns’ participation in multiple March healthcare investor conferences, pr...

Analysis

This announcement details Terns’ participation in multiple March healthcare investor conferences, providing additional visibility for its clinical-stage oncology programs. Set against recent milestones—large December 2025 offerings, detailed 2026 priorities, and board and employee equity grants—investors may focus on the quality of updates delivered at these events. Key watchpoints include any new data, timeline refinements, or strategic changes that could augment the existing growth narrative.

AI-generated analysis. Not financial advice.

FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March.

TD Cowen's 46^th Annual Health Care Conference
Format: Fireside Chat
Date and Time: Monday, March 2, 2026 at 3:50 p.m. ET
Location: Boston, MA

Leerink Global Healthcare Conference
Format: Fireside Chat
Date and Time: Monday, March 9, 2026 at 1:40 p.m. ET
Location: Miami, FL

Barclays 28^th Annual Global Healthcare Conference
Format: 1x1 Meetings
Date: Tuesday, March 10, 2026
Location: Miami, FL

The Citizens Life Sciences Conference
Format: Fireside Chat
Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ET
Location: Miami, FL

Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.

About Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for CML. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
CG Life
media@ternspharma.com

FAQ

When will Terns Pharmaceuticals (TERN) present at the TD Cowen 46th Annual Health Care Conference?

Terns will present a fireside chat on March 2, 2026 at 3:50 p.m. ET. According to the company, the session takes place in Boston and will be available via live webcast on Terns' investor relations page.

How can investors watch Terns Pharmaceuticals (TERN) at the Leerink Global Healthcare Conference on March 9, 2026?

Investors can watch a live webcast of Terns' Leerink fireside chat on March 9, 2026 at 1:40 p.m. ET. According to the company, the webcast will be hosted on the Terns investor relations website with a replay archived afterward.

Is Terns Pharmaceuticals (TERN) meeting with investors at the Barclays Global Healthcare Conference on March 10, 2026?

Yes. Terns' management will take part in 1x1 meetings on March 10, 2026 in Miami. According to the company, these meetings are scheduled at the Barclays 28th Annual Global Healthcare Conference and are not listed as public webcasts.

When and where is Terns Pharmaceuticals (TERN) speaking at The Citizens Life Sciences Conference?

Terns will hold a fireside chat on March 11, 2026 at 9:00 a.m. ET in Miami. According to the company, the presentation will be webcast live and a replay will be archived on Terns' investor relations page for at least 30 days.

How long will Terns Pharmaceuticals (TERN) keep replays of the March 2026 conference webcasts available?

Terns will archive webcast replays for at least 30 days following each presentation. According to the company, live webcasts and subsequent replays will be accessible via the Terns investor relations website during that period.